Immune regulation in chronic hepatitis C virus infection

References

• Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816.
   PubMed Web of Science ®Google Scholar
• Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut. 2012;61:1226–1234.
   PubMed Web of Science ®Google Scholar
• Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: Many shades of gray. Front Immunol. 2014;5:1–19.
   PubMed Web of Science ®Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302:659–662.
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197:1645–1655.
   PubMed Web of Science ®Google Scholar
• Jo J, Aichele U, Kersting N, et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology. 2009;136:1391–1401.
   PubMed Web of Science ®Google Scholar
• Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8:12–22.
   PubMedGoogle Scholar
• Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis. 2004;4:437–444.
   PubMed Web of Science ®Google Scholar
• Thein H-H, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids. 2008;22:1979–1991.
   PubMed Web of Science ®Google Scholar
• Grabowska AM, Lechner F, Klenerman P, et al. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol. 2001;31:2388–2394.
   PubMed Web of Science ®Google Scholar
• Accapezzato D, Francavilla V. Hepatic expansion of a virus-specific regulatory CD8^+ T cell population in chronic hepatitis C virus infection. J Clin. 2004;113:2–11.
   Google Scholar
• Nitschke K, Flecken T, Schmidt J, et al. Tetramer enrichment reveals the presence of phenotypically diverse hepatitis C virus-specific CD8 + T cells in chronic infection. J Virol. 2015;89:25–34.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;131:492–499.
   Web of Science ®Google Scholar
• Penna A, Pilli M, Zerbini A, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology. 2007;45:588–601.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, He X-S, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447–3458.
   PubMed Web of Science ®Google Scholar
• Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol. 2007;81:2545–2553.
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Palmer BE, Kassam N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009;83:9122–9130.
   PubMed Web of Science ®Google Scholar
• Nakamoto N, Kaplan DE, Coleclough J, et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology. 2008;134:1927–1937.
   PubMed Web of Science ®Google Scholar
• Bucks CM, Norton JA, Boesteanu AC, et al. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol. 2009;182:6697–6708.
   PubMed Web of Science ®Google Scholar
• Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583–594.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet D, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–49.
   PubMed Web of Science ®Google Scholar
• De Maria A, Fogli M, Mazza S, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol. 2007;37:445–455.
   PubMed Web of Science ®Google Scholar
• Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta. 2013;1832:1061–1069.
   PubMed Web of Science ®Google Scholar
• Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest. 2010;40:851–863.
   PubMed Web of Science ®Google Scholar
• Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–874.
   PubMed Web of Science ®Google Scholar
• Thoens C, Berger C, Trippler M, et al. KIR2DL3+ NKG2A[N/A]− natural killer cells are associated with protection from productive hepatitis C virus infection in people who inject drugs . J Hepatol. 2013;61:475–481.
   Web of Science ®Google Scholar
• Werner JM, Heller T, Gordon AM, et al. Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection. Hepatology. 2013;58:1621–1631.
   PubMed Web of Science ®Google Scholar
• Alter G, Jost S, Rihn S, et al. Reduced frequencies of NKp30 + NKp46+, CD161+, and NKG2D + NK cells in acute HCV infection may predict viral clearance. J Hepatol. 2011;55:278–288.
   PubMed Web of Science ®Google Scholar
• Pelletier S, Drouin C, Bédard N, et al. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol. 2010;53:805–816.
   PubMed Web of Science ®Google Scholar
• Ahlenstiel G, Titerence RH, Koh C, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology. 2010;138:325–335.e2.
   PubMed Web of Science ®Google Scholar
• Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology. 2012;55:39–48.
   PubMed Web of Science ®Google Scholar
• Golden-mason L, Hurtado CEW, Cheng L, et al. Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3. Clin Immunol. 2015;158:114–125.
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology. 2009;137:1151–1160.e7.
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev. 2013;255:68–81.
   PubMed Web of Science ®Google Scholar
• Zeromski J, Mozer-Lisewska I, Kaczmarek M, et al. NK cells prevalence, subsets and function in viral hepatitis C. Arch Immunol Ther Exp (Warsz). 2011;59:449–455.
   PubMed Web of Science ®Google Scholar
• Lassen MG, Lukens JR, Dolina JS, et al. Intrahepatic IL-10 maintains NKG2A + Ly49- liver NK cells in a functionally hyporesponsive state. J Immunol. 2010;184:2693–2701.
   PubMed Web of Science ®Google Scholar
• Fugier E, Marche H, Thélu M-A, et al. Functions of liver natural killer cells are dependent on the severity of liver inflammation and fibrosis in chronic hepatitis C. PLoS One. 2014;9:e95614.
   PubMed Web of Science ®Google Scholar
• Varchetta S, Mele D, Mantovani S, et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology. 2012;56:841–849.
   PubMed Web of Science ®Google Scholar
• Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. Gut. 2014;63:151–524.
   Web of Science ®Google Scholar
• Glässner A, Eisenhardt M, Krämer B, et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Investig. 2012;92:967–977.
   PubMed Web of Science ®Google Scholar
• Gur C, Doron S, Kfir-Erenfeld S, et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut. 2012;61:885–893.
   PubMed Web of Science ®Google Scholar
• Krämer B, Körner C, Kebschull M, et al. Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology. 2012;56:1201–1213.
   PubMed Web of Science ®Google Scholar
• Nielsen N, Ødum N, Ursø B, et al. Cytotoxicity of CD56 bright NK cells towards autologous activated CD4 + T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One. 2012;7:1–10.
   Web of Science ®Google Scholar
• Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003;112:1310–1312.
   PubMed Web of Science ®Google Scholar
• Hartling HJ, Gaardbo JC, Ronit A, et al. CD4(+) and CD8(+) regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Scand J Immunol. 2012;76:294–305.
   PubMed Web of Science ®Google Scholar
• Rushbrook SM, Ward SM, Unitt E, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005;79:7852–7859.
   PubMed Web of Science ®Google Scholar
• Cabrera R, Tu Z, Xu Y, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004;40:1062–1071.
   PubMed Web of Science ®Google Scholar
• Claassen MAA, de Knegt RJ, Tilanus HW, et al. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol. 2010;52:315–321.
   PubMed Web of Science ®Google Scholar
• Sturm N, Thélu M-A, Camous X, et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol. 2010;53:25–35.
   PubMed Web of Science ®Google Scholar
• Ward SM, Fox BC, Brown PJ, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol. 2007;47:316–324.
   PubMed Web of Science ®Google Scholar
• Chang J-B, Xue R, Zhou Z-X, et al. Prediction of antiviral efficacy in patients with chronic hepatitis C by changes in forkhead box protein 3 levels. Exp Ther Med. 2014;8:165–168.
   PubMed Web of Science ®Google Scholar
• Speletas M, Argentou N, Germanidis G, et al. Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 2011;2011:827565.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ponce C, Dominguez-Villar M, Aguado E, et al. CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLoS One. 2014;9:e85191.
   PubMed Web of Science ®Google Scholar
• Zhai N, Chi X, Li T, et al. Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patients. Cell Mol Immunol. 2015;12:743–749.
   PubMed Web of Science ®Google Scholar
• Hall CHT, Kassel R, Tacke RS, et al. HCV + hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS One. 2010;5:1–10.
   Web of Science ®Google Scholar
• Harfouch S, Guiguet M, Valantin M-A, et al. Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. J Hepatol. 2012;56:1259–1268.
   PubMed Web of Science ®Google Scholar
• Halota W, Ferenci P, Kozielewicz D, et al. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. J Viral Hepat. 2015;22:651–657.
   PubMed Web of Science ®Google Scholar
• Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat. 2009;16:223–229.
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Szabo G. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol. 2008;84:614–622.
   PubMed Web of Science ®Google Scholar
• Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev. 2012;36:663–683.
   PubMed Web of Science ®Google Scholar
• Cusick MF, Schiller JJ, Gill JC, et al. Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol. 2011;2011:806061.
   PubMedGoogle Scholar
• Cho H, Kikuchi M, Li Y, et al. Induction of multiple immune regulatory pathways with differential impact in HCV/HIV coinfection. Front Immunol. 2014;5:265.
   PubMed Web of Science ®Google Scholar
• Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 2004;113:963–972.
   PubMed Web of Science ®Google Scholar
• Abel M, Sène D, Pol S, et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006;44:1607–1616.
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Paek E, Kodys K, et al. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology. 2008;135:2119–2127.
   PubMed Web of Science ®Google Scholar
• Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence. 2012;3:610–620.
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy – review of a new approach. Pharmacol Rev. 2003;55:241–269.
   PubMed Web of Science ®Google Scholar
• Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180:5771–5777.
   PubMed Web of Science ®Google Scholar
• Niesen E, Schmidt J, Flecken T, et al. Suppressive Effect of Interleukin 10 on Priming of Naive Hepatitis C Virus –. Specific CD8 + T Cells. J Infect Dis. 2015;10:821–826.
   Google Scholar
• Flynn JK, Dore GJ, Hellard M, et al. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat. 2011;18:549–561.
   PubMed Web of Science ®Google Scholar
• Rushbrook SM, Hoare M, Alexander GJM. T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther. 2007;7:1689–1703.
   PubMed Web of Science ®Google Scholar
• Aroucha DCBL, do Carmo RF, Moura P, et al. High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine. 2013;62:421–425.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lauwers GY, Lau JYN, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000;118:655–660.
   PubMed Web of Science ®Google Scholar
• Schon H, Weiskirchen R. Immunomodulatory effects of transforming growth factor-β in the liver. Hepatobiliary Surg Nutr. 2014;3:386–406.
   PubMedGoogle Scholar
• Benzoubir N, Lejamtel C, Battaglia S, et al. HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment. J Hepatol. 2013;59:1160–1168.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Beckett O, Ma Q, et al. Transforming growth factor-β signaling curbs thymic negative selection promoting regulatory T cell development. Immunity. 2011;32:642–653.
   Web of Science ®Google Scholar
• Robertson I, Rifkin D. Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation. Cytokine Growth Factor. 2012;29:997–1003.
   Google Scholar
• Friedman SL. Mechanisms of Hepatic Fibrogenesis. Gastroenterology. 2010;134:1655–1669.
   Web of Science ®Google Scholar
• Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578–10604.
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007;56:284–292.
   PubMed Web of Science ®Google Scholar
• Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology. 2006;43:771–779.
   PubMed Web of Science ®Google Scholar
• Weng HL, Liu Y, Chen JL, et al. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology. 2009;50:230–243.
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–655.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295–312.
   PubMed Web of Science ®Google Scholar
• Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011;157:163–179.
   PubMed Web of Science ®Google Scholar
• Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67:129–139.
   PubMed Web of Science ®Google Scholar
• Fan H-X, Tang H. Complex interactions between microRNAs and hepatitis B/C viruses. World J Gastroenterol. 2014;20:13477–13492.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37:460–465.
   PubMed Web of Science ®Google Scholar
• Redis RS, Calin S, Yang Y, et al. Cell-to-cell miRNA transfer: From body homeostasis to therapy. Pharmacol Ther. 2012;136:169–174.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654.
   PubMed Web of Science ®Google Scholar
• Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1:106–113.
   PubMedGoogle Scholar
• Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.
   PubMed Web of Science ®Google Scholar
• Tsai W-C, Hsu S-D, Hsu C-S, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884–2897.
   PubMed Web of Science ®Google Scholar
• Hsu S-H, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871–2883.
   PubMed Web of Science ®Google Scholar
• Jopling CL, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008;4:77–85.
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–1581.
   PubMed Web of Science ®Google Scholar
• Li Y, Masaki T, Yamane D, et al. Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci USA.2013;110:1881–1886.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–922.
   PubMed Web of Science ®Google Scholar
• Cheng M, Si Y, Niu Y, et al. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol. 2013;87:9707–9718.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Aly HH, Tajima A, et al. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol. 2009;50:453–460.
   PubMed Web of Science ®Google Scholar
• Hou W, Tian Q, Zheng J, et al. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology. 2010;51:1494–1504.
   PubMed Web of Science ®Google Scholar
• Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542–552.
   PubMed Web of Science ®Google Scholar
• Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2011;106:1663–1669.
   PubMed Web of Science ®Google Scholar
• Roderburg C, Benz F, Vargas Cardenas D, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015;35:1172–1184.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Farid WRR, Sonneveld MJ, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat. 2013;20:158–166.
   PubMed Web of Science ®Google Scholar
• Bala S, Tilahun Y, Taha O, et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med. 2012;10:151.
   PubMed Web of Science ®Google Scholar
• Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6:e23937.
   PubMed Web of Science ®Google Scholar
• Sarma NJ, Tiriveedhi V, Crippin JS, et al. Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis. J Virol. 2014;88:3733–3743.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Kohlhaas S, Lu D, et al. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253:146–157.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei W, Cheng N, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology .2012;56:1631–1640.
   PubMed Web of Science ®Google Scholar
• Grek M, Piekarska A, Bartkowiak J, et al. Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. Int J Mol Med. 2011;28:875–880.
   PubMed Web of Science ®Google Scholar
• Bala S, Marcos M, Kodys K, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011;286:1436–1444.
   PubMed Web of Science ®Google Scholar
• Mohammed KI, Adel LA, Ali-Eldin FA, et al. Expression of Toll like receptors 3 & 7 in peripheral blood from patients with chronic hepatitis C virus infection and their correlation with interferon-alpha. Egypt J Immunol. 2013;20:13–22.
   PubMedGoogle Scholar
• Firdaus R, Biswas A, Saha K, et al. Modulation of TLR 3, 7 and 8 expressions in HCV genotype 3 infected individuals: potential correlations of pathogenesis and spontaneous clearance. Biomed Res Int. 2014;2014:491064.
   PubMed Web of Science ®Google Scholar
• Yang Q, Fu S, Wang J. Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758. Arch Virol. 2014;159:2997–3003.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Wang H, et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog. 2013;9:e1003248.
   PubMed Web of Science ®Google Scholar
• Bihrer V, Waidmann O, Friedrich-Rust M, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One. 2011;6:e26971.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang Y, Wei J, et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer. 2013;13:469.
   PubMed Web of Science ®Google Scholar
• Hu S, Tao R, Wang S, et al. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumour Biol. 2015;36:5467–5472.
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658.
   PubMed Web of Science ®Google Scholar
• Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–2136.
   PubMed Web of Science ®Google Scholar
• Noetel A, Kwiecinski M, Elfimova N, et al. microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol. 2012;3:49
   PubMed Web of Science ®Google Scholar
• Trebicka J, Anadol E, Elfimova N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013;58:234–239.
   PubMed Web of Science ®Google Scholar
• Jansen C, Reiberger T, Huang J, et al. Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One. 2015;10:e0116768.
   PubMed Web of Science ®Google Scholar
• Estrabaud E, Lapalus M, Broët P, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol. 2014;88:6394–6402.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Iizuka M, Sekiya Y, et al. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun. 2010;391:316–321.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ghazwani M, Li J, et al. MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase. Biochem Biophys Res Commun. 2014;446:940–944.
   PubMed Web of Science ®Google Scholar
• Roderburg C, Urban G-W, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53:209–218.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Friedman RC, Marquez RT, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis. 2011;203:1753–1762.
   PubMed Web of Science ®Google Scholar
• Marquez RT, Bandyopadhyay S, Wendlandt EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010;90:1727–1736.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Tanaka M, Toyoda H, et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics. 2010;3:48.
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Krol J, Markiewicz I, et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009;15:31–33.
   PubMed Web of Science ®Google Scholar
• Köberle V, Waidmann O, Kronenberger B, et al. Serum microRNA-122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. J Viral Hepat. 2013;20:530–535.
   PubMed Web of Science ®Google Scholar
• Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685–1694.
   PubMed Web of Science ®Google Scholar
• Jiang M, Broering R, Trippler M, et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat. 2014;21:99–110.
   PubMed Web of Science ®Google Scholar
• Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011;31:68–77.
   PubMed Web of Science ®Google Scholar
• EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• Abdel-Hakeem MS, Bédard N, Badr G, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol. 2010;84:10429–10435.
   PubMed Web of Science ®Google Scholar
• Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology. 2002;36:743–754.
   PubMed Web of Science ®Google Scholar
• Badr G, Bédard N, Abdel-Hakeem MS, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol. 2008;82:10017–10031.
   PubMed Web of Science ®Google Scholar
• Su S, He H, Kong L, et al. Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial. PLoS One. 2014;9:e93620.
   PubMed Web of Science ®Google Scholar
• Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61:538–543.
   PubMed Web of Science ®Google Scholar
• Hartling HJ, Birch C, Gaardbo JC, et al. T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen. Apmis 2015;123:903–911.
   PubMed Web of Science ®Google Scholar
• Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology. 2015;149:190–200.e2.
   PubMed Web of Science ®Google Scholar
• Spaan M, van Oord G, Kreefft K, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis. 2016;213:216–223.
   PubMed Web of Science ®Google Scholar
• Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141:1231–1239.e2.
   PubMed Web of Science ®Google Scholar
• Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol. 2013;59:38–44.
   PubMed Web of Science ®Google Scholar